Target Validation Information | |||||
---|---|---|---|---|---|
TTD ID | T86385 | ||||
Target Name | Cathepsin G (CTSG) | ||||
Type of Target |
Clinical trial |
||||
Drug Potency against Target | Aloxistatin | Drug Info | IC50 = 1100 nM | [2] | |
Delanzomib | Drug Info | IC50 = 2110 nM | [3] | ||
JNJ-10311795 | Drug Info | Ki = 38 nM | [1] | ||
Action against Disease Model | Dermolastin | Drug Info | N-glycosylation and biological activity of recombinant h uMan alpha1-antitrypsin expressed in a novel h uMan neuronal cell line. | [4] | |
References | |||||
REF 1 | Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase. J Med Chem. 2007 Apr 19;50(8):1727-30. | ||||
REF 2 | Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing. J Biol Chem. 2007 Jul 20;282(29):20836-46. | ||||
REF 3 | Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J Med Chem. 2008 Feb 28;51(4):1068-72. | ||||
REF 4 | N-glycosylation and biological activity of recombinant human alpha1-antitrypsin expressed in a novel human neuronal cell line. Biotechnol Bioeng. 2011 Sep;108(9):2118-28. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.